Radiation sensitization of human cancer cells in vivo by inhibiting the activity of PI3K using LY294002

International Journal of Radiation Oncology Biology Physics

Volumn 56, Issue 3, 2003, Pages 846-853

  Gupta, Anjali K ^a   Cerniglia, George J ^a   Mick, Rosemarie ^a   Ahmed, Mona S ^a   Bakanauskas, Vincent J ^a   Muschel, Ruth J ^a   McKenna, W Gillies ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

In vivo; LY294002; PI3K; Radiation resistance

Indexed keywords

BIOASSAY; GROWTH KINETICS; TISSUE CULTURE; TUMORS;

ANTITUMOR EFFECTS;

RADIOTHERAPY;

2 MORPHOLINO 8 PHENYLCHROMONE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CARCINOMA; CANCER CELL CULTURE; CANCER RADIOTHERAPY; CELL LYSATE; CLONOGENESIS; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOWNSTREAM PROCESSING; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GENE AMPLIFICATION; GENE MUTATION; GENE TARGETING; HUMAN; HUMAN CELL; IN VIVO STUDY; LETHALITY; LETHARGY; MEDICAL DOCUMENTATION; MOLECULAR CLONING; MOUSE; NONHUMAN; NUDE MOUSE; ONCOGENE H RAS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RADIOSENSITIZATION; RANDOMIZATION; RESPIRATION DEPRESSION; STATISTICAL SIGNIFICANCE; WESTERN BLOTTING; XENOGRAFT;

EID: 0038281227     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0360-3016(03)00214-1     Document Type: Article

References (33)

1. Girinsky T., Lubin R., Pignon J.P., et al. Predictive value of in vitro radiosensitivity parameters in head and neck cancers and cervical carcinomas Preliminary correlations with local control and overall survival . Int J Radiat Oncol Biol Phys. 25:1993;147-148.
2. West C.M., Davidson S.E., Roberts S.A., et al. Intrinsic radiosensitivity and prediction of patient response to radiotherapy for carcinoma of the cervix. Br J Cancer. 68:1993;819-823.
3. Bos J.L. Ras oncogenes in human cancer A review . Cancer Res. 49:1989;4682-4689.
4. Li D. Molecular epidemiology of pancreatic cancer. CancerJ. 7:2001;259-265.
5. Ahrendt S.A., Yang S.C., Wu L., et al. Molecular assessment of lymph nodes in patients with resected stage I non-small cell lung cancer Preliminary results of a prospective study . J Thorac Cardiovasc Surg. 123:2002;466-474.
6. Bezieau S., Devilder M.C., Avet-Loiseau H., et al. High incidence of N and K-Ras activating mutations in multiple myeloma and primary plasma cell leukemia at diagnosis. Hum Mutat. 18:2001;212-224.
7. Klapper L.N., Kirschbaum M.H., Sela M., et al. Biochemical and clinical implications of ErbB/HER signaling network of growth factor receptors. Adv Cancer Res. 77:2000;25-79.
8. Dassonville O., Formento J.L., Francoual M., et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol. 11:1993;1873-1878.
9. Shin D.M., Ro J.Y., Hong W.K., et al. Dysregulation of epidermal growth factor receptor expression in premalignant lesions during head and neck tumorigenesis. Cancer Res. 54:1994;3153-3159.
10. Ohsaki Y., Tanno S., Fujita Y., et al. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep. 7:2000;603-607.
11. Pirinen R., Lipponen P., Syrjanen K. Expression of epidermal growth factor receptor (EGFR) in breast cancer as related to clinical, prognostic and cytometric factors. Anticancer Res. 15:1995;2835-2840.
12. Ashley D.M., Batra S.K., Bigner D.D. Monoclonal antibodies to growth factors and growth factor receptors Their diagnostic and therapeutic potential in brain tumors . J Neurooncol. 35:1997;259-273.
13. Kim Y.S., Konoplev S.N., Montemurro F., et al. HER-2/neu overexpression as a poor prognostic factor for patients with metastatic breast cancer undergoing high-dose chemotherapy with autologous stem cell transplantation. Clin Cancer Res. 7:2001;4008-4012.
14. Brabender J., Danenberg K.D., Metzger R., et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res. 7:2001;1850-1855.
15. Herbst R.S., Langer C.J. Epidermal growth factor receptors as a target for cancer treatment the emerging role of IMC-C225 in the treatment of lung and head and neck cancers . Semin Oncol. 29:(Suppl 4):2002;27-36.
16. Lammering G., Hewit T.H., Hawkins W.T., et al. Epidermal growth factor receptor as a genetic therapy target for carcinoma cell radiosensitization. J Natl Cancer Inst. 93:2001;921-929.
17. Ross J.S., Fletcher J.A. The HER-2/neu oncogene in breast cancer Prognostic factor, predictive factor, and target for therapy . Stem Cells. 16:1998;413-428.
18. Vogel C.L., Cobleigh M.A., Tripathy D., et al. First-line Herceptin monotherapy in matastatic breast cancer. Oncology. 61:(Suppl 2):2001;37-42.
19. Baselga J., Pfister D., Cooper M.R., et al. Phase I studies of anti-epidermal growth factor receptor chimeric antibody C225 alone and in combination with cisplatin. J Clin Oncol. 18:2000;904-914.
20. Gupta A.K., Bakanauskas V.J., Cerniglia G.J., et al. The Ras radiation resistance pathway. Cancer Res. 61:2001;4278-4282.
21. Chan T.O., Rodeck U., Chan A.M., et al. Small GTPases and tyrosine kinases coregulate a molecular switch in the phosphoinositide 3-kinase regulatory subunit. Cancer Cell. 1:2002;181-911.
22. Unnisa I., Schriml L.M., Dean M. Mutational spectra of PTEN/MMAC1 gene A tumor suppressor with lipid phosphatase activity . J Natl Cancer Inst. 91:2000;1922-1932.
23. Poetsch M., Lorenz G., Kleist B. Detection of new PTEN/MMAC1 mutations in head and neck squamous cell carcinomas with loss of chromosome 10. Cancer Genet Cytogenet. 132:2002;20-24.
24. Dicuonzo G., Angeletti S., Garcia-Foncillas J., et al. Colorectal carcinomas and PTEN/MMAC1 gene mutations. Clin Cancer Res. 7:2001;4049-4053.
25. Tada K., Shiraishi S., Kamiryo T., et al. Analysis of loss of heterozygosity on chromosome 10 in patients with malignant astrocytic tumors Correlation with patient age and survival . J Neurosurg. 95:2001;651-659.
26. Gurumurthy S., Vasudevan K.M., Rangnekar V.M. Regulation of apoptosis in prostate cancer. Cancer Metastasis Rev. 20:2001;225-243.
27. Depowski P.L., Rosenthal S.I., Ross J.S. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod Pathol. 14:2001;672-676.
28. Wick W., Furnari F.B., Naumann U., et al. PTEN gene transfer in human malignant glioma Sensitization to irradiation and CD95L-induced apoptosis . Oncogene. 18:1999;3936-3943.
29. Gupta A.K., McKenna W.G., Weber C.N., et al. Local recurrence in head and neck cancer Relationship to radiation resistance and signal transduction . Clin Cancer Res. 8:2002;885-892.
30. Sasaki T., Irie-Sasaki J., Jones R.G., et al. Function of PI3K in thymocyte development, T cell activation, and neutrophil migration. Science. 287:2000;1040-1046.
31. Hu L., Zaloudek C., Mills G.B., et al. In vivo and in vitro ovarian carcinoma growth inhibition by a phosphatidylinositol 3-kinase inhibitor (LY294002). Clin Cancer Res. 6:2000;880-886.
32. Semba S., Itoh N., Ito M., et al. The in vitro and in vivo effects of 2-(4-morpholinyl)-8-pheny chrome (LY294002), a specific inhibitor of phosphatidylinositol 3-kinase in human colon cancer cells. Clin Cancer Res. 8:2002;1957-1963.
33. Edwards E., Geng L., Tan J., et al. Phosphatidylinositol 3-kinase/Akt signaling in the response of vascular endothelium to ionizing radiation. Cancer Res. 62:2002;4671-4677.